Processa Pharmaceuticals (NASDAQ:PCSA) Posts Quarterly Earnings Results, Beats Estimates By $0.47 EPS

Processa Pharmaceuticals (NASDAQ:PCSA) released its quarterly earnings data on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.47, Zacks reports.

Processa Pharmaceuticals Stock Down 13.4 %

NASDAQ PCSA opened at $0.24 on Friday. Processa Pharmaceuticals has a 52 week low of $0.15 and a 52 week high of $3.10. The business has a 50 day moving average price of $0.33 and a 200-day moving average price of $0.69. The company has a market cap of $1.25 million, a price-to-earnings ratio of -0.07 and a beta of 1.36.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.